Pharma: Clinic Roundup
Friday, July 12, 2013
Ipsen SA, of Paris, reported results from the primary endpoint of the CLARINET study, which is testing the effect of Somatuline Autogel 120 mg on tumor progression-free survival in patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), showing that treatment with Somatuline was found to be statistically significantly superior to placebo in extending time to either disease progression or death.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.